Evidence map›Paper›PMID 40524948›Full record

ArticleClinical parkinsonism & related disorders2025

Mesocorticolimbic dopaminergic innervation modulates Levodopa-related improvements in gait in older slow walking Adults: A [

N Paalanen, S Roytman, M van Emde Boas, A Biddix, A Luker, F Michalakis, G Carli, P Kanel, C Pongmala, R Koeppe and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Striatal dopamine and skeletal muscle energy metabolism in older adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

N PaalanenDepartment of Neurology, University of Michigan, Ann Arbor, MI 48105-9755, USA.
S RoytmanDepartment of Radiology, University of Michigan, Ann Arbor, MI 48105-9755, USA.
M van Emde BoasDepartment of Radiology, University of Michigan, Ann Arbor, MI 48105-9755, USA.
A BiddixDepartment of Radiology, University of Michigan, Ann Arbor, MI 48105-9755, USA.
A LukerDepartment of Radiology, University of Michigan, Ann Arbor, MI 48105-9755, USA.
F MichalakisDepartment of Radiology, University of Michigan, Ann Arbor, MI 48105-9755, USA.
G CarliDepartment of Neurology, University of Michigan, Ann Arbor, MI 48105-9755, USA.
P KanelDepartment of Radiology, University of Michigan, Ann Arbor, MI 48105-9755, USA.
C PongmalaDepartment of Radiology, University of Michigan, Ann Arbor, MI 48105-9755, USA.
R KoeppeDepartment of Radiology, University of Michigan, Ann Arbor, MI 48105-9755, USA.
L M ChahineDepartment of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.
C RosanoDepartment of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.
N I BohnenDepartment of Neurology, University of Michigan, Ann Arbor, MI 48105-9755, USA.

Funding

NIA NIH HHS U01 AG061393
6 · The paper itself

Abstract

Purpose: Slow walking in healthy older adults may result from multifactorial deficits involving the muscular, peripheral, and central nervous systems. While mobility depends on these systems, the brain's neuromodulatory capacity may offer insights for interventions. This open-label imaging study tested whether the dopaminergic system serves as a resilience mechanism for gait in the elderly. Using [ Methods: Slow walking older adults without clinical evidence of PD (n = 9) were pre-treated with carbidopa 25 mg one tablet TID for three days, followed by carbidopa-levodopa 25/100 mg starting at one tablet TID for three days and then increased to 1.5 tablets of carbidopa-levodopa 25/100 mg TID daily for four days, as tolerated. [ Results: Levodopa treatment resulted in improved gait speed ( Conclusion: These preliminary findings suggest that the mesocorticolimbic dopaminergic system may be the substrate of a resilience mechanism that can be targeted to manage gait impairments in older adults.

Indexed as

[11C]PE2IDopaminergic resilienceGaitMobilityPET/CT

Identifiers

PMID40524948
PMCPMC12169706

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.